CLYMHealthcare · BiotechnologyThe 15 Wall Street analysts covering Climb Bio, Inc. hold a median 12-month price target of $27 — +86.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 12 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Climb Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Volatility (24): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CLYM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +86.0% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $24 → $30 |
| 8 Sept 2026 | Oppenheimer | Maintains | Outperform | $18 → $25 |
| 4 Sept 2026 | B. Riley Securities | Reiterates | Buy | $26 → $30 |
| 3 Sept 2026 | Baird | Maintains | Outperform | $21 → $25 |
| 3 Sept 2026 | BTIG | Maintains | Buy | $20 → $32 |
| 24 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $20 → $24 |
| 19 Aug 2026 | Wedbush | Reiterates | Outperform | — |
| 19 Aug 2026 | Wedbush | Reiterates | Outperform | $20 |
| 7 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 7 Aug 2026 | Truist Securities | Maintains | Buy | $17 → $25 |
| 27 July 2026 | Wedbush | Maintains | Outperform | — |
| 27 July 2026 | Wedbush | Maintains | Outperform | $17 → $20 |
| 24 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 24 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 June 2026 | Wedbush | Reiterates | Outperform | — |
| 11 June 2026 | BTIG | Maintains | Buy | — |
| 8 June 2026 | BTIG | Reiterates | Buy | — |
| 8 June 2026 | Guggenheim | Initiates | Buy | — |
| 12 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLYM appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Climb Bio, Inc. returned +493.8% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 29% of US stocks
Cheaper than 84% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 28% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Climb Bio, Inc. has a market value of $818.5M and an enterprise value of $636.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$57.6M.
Diluted earnings per share, trailing twelve months: $−0.83.
Free cash flow in the twelve months to 30 June 2026: −$53.1M.
Trailing P/E: −16.2×; forward P/E: −14.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Climb Bio, Inc. employs 28 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Climb Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Climb Bio presented Phase I data for CLYM116, an anti-APRIL "sweeper" antibody being developed for IgA nephropathy. The company said the results support advancing the program into an ongoing Phase II study in China.
Why it matters — The data validate CLYM116's development path and support progress of the company's lead pipeline candidate toward Phase II.
Climb Bio released preliminary data from its ongoing Phase 1 trial of CLYM116 and announced updated strategic plans for treating IgA nephropathy, a kidney disease. The news includes support for an extended dosing schedule for the therapy.
Why it matters — This marks progress in Climb Bio's lead kidney disease program with preliminary trial data and a refined development strategy for IgA nephropathy.
Climb Bio shares reversed course Thursday, falling despite potentially "best-in-class" data for its experimental kidney disease treatment. The stock had previously risen more than 1,300% over 17 months.
Why it matters — The stock's sharp reversal despite encouraging trial data signals investor concerns that could affect Climb Bio's valuation and momentum.
Climb Bio announced Phase 1 data for CLYM116 in IgA nephropathy, showing a prolonged half-life of about 29 days, near-complete APRIL suppression, and 60-75% IgA/Gd-IgA1 suppression through 12 weeks from a single 320 mg dose, supporting every-12-week dosing. The drug was generally well-tolerated with no serious adverse events, and the Phase 2 NAVIGATE-2 trial is ongoing with initial data expected in H1 2027.
Why it matters — The favorable Phase 1 profile supports less frequent dosing, a potential competitive advantage for CLYM116 as Climb Bio advances its IgA nephropathy program toward Phase 2 data and Phase 3 initiation in 2027.
Climb Bio, Inc., a clinical stage biotechnology company developing therapeutics for immune-mediated diseases, announced that members of its executive team will participate in upcoming investor conferences. The announcement was made via press release on September 2, 2026, from Wellesley Hills, Massachusetts.
Why it matters — CLYM watchers would care because management's participation at investor conferences provides opportunities for the company to communicate its pipeline and progress directly to investors.
The 15 Wall Street analysts covering Climb Bio, Inc. have a median 12-month price target of $27, with estimates ranging from $18 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering Climb Bio, Inc., 15 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Climb Bio, Inc. 60 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Climb Bio, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +86.0% from the last close, and Ticker Nerd's factor model ranks Climb Bio, Inc. 60 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Climb Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLYM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $40 over the next 12 months.
Climb Bio, Inc. returned +493.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing monoclonal antibody therapies for immune-mediated diseases.
The most recent item we track (MarketBeat, 3 Sept 2026): "Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug". Climb Bio presented Phase I data for CLYM116, an anti-APRIL "sweeper" antibody being developed for IgA nephropathy. The company said the results support advancing the program into an ongoing Phase II study in China.
Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing monoclonal antibody therapies for immune-mediated diseases. Its current pipeline centers on budoprutug, an anti-CD19 antibody being studied for B-cell mediated and autoantibody-driven conditions, and CLYM116, an anti-APRIL antibody in development for IgA nephropathy. The company’s work is directed at diseases where abnormal immune activity can damage organs and create significant unmet medical need, including kidney and hematologic disorders. Climb Bio operates in the biopharmaceutical sector through preclinical research, clinical development, and translational programs designed to advance differentiated biologic medicines. Based in Wellesley Hills, Massachusetts, Climb Bio is positioned as a specialized developer of targeted immunology assets for complex immune disorders.
CEO Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc · 28 employees · United States · https://climbbio.com
